RVNC [NASD]
Revance Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.04 Insider Own1.90% Shs Outstand68.33M Perf Week-1.86%
Market Cap1.03B Forward P/E- EPS next Y-2.99 Insider Trans0.00% Shs Float64.19M Perf Month1.64%
Income-274.00M PEG- EPS next Q-0.86 Inst Own84.30% Short Float11.13% Perf Quarter-29.94%
Sales89.80M P/S11.42 EPS this Y14.30% Inst Trans2.76% Short Ratio9.11 Perf Half Y-14.94%
Book/sh0.37 P/B38.46 EPS next Y12.20% ROA-45.80% Target Price28.78 Perf Year-51.73%
Cash/sh3.64 P/C3.90 EPS next 5Y11.60% ROE-273.70% 52W Range11.27 - 33.83 Perf YTD-12.81%
Dividend- P/FCF- EPS past 5Y-5.60% ROI-78.70% 52W High-57.94% Beta0.94
Dividend %- Quick Ratio3.90 Sales past 5Y203.90% Gross Margin69.80% 52W Low26.26% ATR0.85
Employees495 Current Ratio4.00 Sales Q/Q90.20% Oper. Margin- RSI (14)52.45 Volatility5.79% 5.87%
OptionableYes Debt/Eq17.64 EPS Q/Q12.40% Profit Margin- Rel Volume1.07 Prev Close14.55
ShortableYes LT Debt/Eq16.90 EarningsMay 10 AMC Payout- Avg Volume784.62K Price14.23
Recom1.80 SMA206.73% SMA50-2.80% SMA200-14.39% Volume838,427 Change-2.20%
Oct-25-21Downgrade Wells Fargo Overweight → Equal Weight $35 → $17
Oct-15-20Reiterated Needham Buy $36 → $42
Aug-11-20Resumed Mizuho Buy $32
Mar-23-20Downgrade Goldman Buy → Neutral $32 → $15
Dec-02-19Initiated Goldman Buy
Oct-30-19Upgrade Wells Fargo Market Perform → Outperform $20
Jun-11-19Initiated Barclays Overweight $28
Feb-15-19Initiated Wells Fargo Market Perform
Feb-14-19Initiated H.C. Wainwright Buy $25
Jan-29-19Initiated Stifel Buy $50
Nov-16-18Upgrade Guggenheim Neutral → Buy
Sep-17-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Apr-20-18Reiterated Mizuho Buy $54 → $48
Mar-27-18Initiated Needham Buy $42
Mar-05-18Initiated Goldman Buy $60
Jan-09-18Downgrade Guggenheim Buy → Neutral
Dec-06-17Reiterated Mizuho Buy $37 → $54
Dec-06-17Initiated Guggenheim Buy $42
Nov-27-17Initiated Barclays Overweight $31
Nov-17-17Initiated Mizuho Buy $37
Jun-15-22 08:19AM  
May-23-22 08:00AM  
May-17-22 06:46AM  
May-10-22 05:45PM  
04:05PM  
May-05-22 06:45PM  
May-03-22 08:00AM  
Apr-21-22 04:05PM  
Apr-08-22 03:00PM  
Mar-28-22 08:00AM  
Mar-22-22 05:03AM  
Mar-21-22 08:00AM  
Mar-08-22 08:00AM  
Mar-02-22 08:00AM  
Feb-28-22 04:05PM  
Feb-23-22 02:06PM  
Feb-22-22 08:00AM  
Feb-21-22 03:00PM  
Feb-08-22 01:38PM  
Feb-07-22 01:50PM  
Jan-25-22 01:38PM  
11:02AM  
Jan-18-22 04:05PM  
Jan-13-22 01:38PM  
Jan-07-22 08:00AM  
Dec-31-21 07:13PM  
06:13PM  
02:50PM  
01:00PM  
Dec-30-21 11:15PM  
10:00PM  
06:01PM  
05:36PM  
04:00PM  
03:23PM  
11:15AM  
09:36AM  
09:30AM  
Dec-29-21 11:20PM  
07:01PM  
06:01PM  
04:21PM  
03:15PM  
10:15AM  
Dec-28-21 06:01PM  
04:00PM  
02:36PM  
11:30AM  
10:00AM  
Dec-27-21 05:58PM  
03:38PM  
03:15PM  
02:22PM  
12:30PM  
11:00AM  
Dec-26-21 10:40PM  
05:20PM  
08:26AM  
Dec-25-21 06:55PM  
08:22AM  
Dec-24-21 03:20PM  
01:44PM  
11:00AM  
Dec-23-21 11:00PM  
09:52PM  
06:58PM  
05:10PM  
02:15PM  
09:30AM  
Dec-22-21 08:02PM  
06:49PM  
05:00PM  
04:34PM  
02:32PM  
09:40AM  
Dec-21-21 11:32PM  
09:35PM  
08:05PM  
06:57PM  
06:45PM  
05:00PM  
03:40PM  
01:00PM  
11:00AM  
09:20AM  
06:06AM  
Dec-20-21 11:01PM  
07:20PM  
06:53PM  
05:53PM  
03:41PM  
03:30PM  
11:00AM  
11:00AM  
11:00AM  
10:00AM  
09:40AM  
09:30AM  
Dec-19-21 09:00PM  
06:32PM  
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Russell Angus C.DirectorDec 13Buy15.746,400100,74126,913Dec 15 08:17 PM
Rankin AubreyPresident, Innovation & TechDec 03Buy14.4330,000432,87695,463Dec 06 08:34 PM
Foley Mark JCEONov 29Buy12.9040,000515,924110,913Nov 29 09:24 PM
Moxie DwightSVP, GC & SecretarySep 27Sale30.001,67550,25047,804Sep 28 09:23 PM
Rankin AubreyPresident, Innovation & TechAug 16Sale26.349,364246,65965,463Aug 17 06:20 PM
Rankin AubreyPresident, Innovation & TechJul 28Sale30.0654,3321,632,960154,302Jul 30 08:57 PM
Rankin AubreyPresident, Innovation & TechJul 26Sale29.7255,3821,645,953355,943Jul 28 09:48 PM